Yet again we have some news on Acomplia from another part of the world and yet another clinical trial. A study of 526 obese patients in Japan showed that Acomplia had a dramatic effect on the reduction of the dangerous visceral fat which surrounds certain organs such as the liver. The study showed that those taking the normal 20 mg a day dose managed a reduction in visceral fat twice that of those on the placebo.
The visceral fat contains large insulin resistant fat cells which can lead to type 2 diabetes and heart disease.
In a separate announcement, Sanofi Aventis has said that it will not seek approval for Acomplia in the US for use in obese patients for around 3-4 years. This will be a huge disappointment to many overweight Americans, many of whom contact us on a daily basis looking for Acomplia. Unfortunately, owing to regulatory restrictions, we cannot prescribe medication to American residents.
Remember Me
a@href@title, strike
Consultation, Diagnosis & Prescription
Telephone support:020 7419 5064